North Star Investment Management Corp. Buys 13,000 Shares of Array BioPharma Inc. (ARRY)

North Star Investment Management Corp. lifted its stake in Array BioPharma Inc. (NASDAQ:ARRY) by 26.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 63,000 shares of the biopharmaceutical company’s stock after purchasing an additional 13,000 shares during the period. North Star Investment Management Corp.’s holdings in Array BioPharma were worth $806,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Northern Trust Corp boosted its position in shares of Array BioPharma by 8.5% in the 2nd quarter. Northern Trust Corp now owns 2,130,493 shares of the biopharmaceutical company’s stock worth $17,832,000 after purchasing an additional 166,031 shares during the last quarter. New York State Common Retirement Fund boosted its position in shares of Array BioPharma by 6.4% in the 2nd quarter. New York State Common Retirement Fund now owns 195,300 shares of the biopharmaceutical company’s stock worth $1,635,000 after purchasing an additional 11,699 shares during the last quarter. Nationwide Fund Advisors boosted its position in shares of Array BioPharma by 12.8% in the 2nd quarter. Nationwide Fund Advisors now owns 125,993 shares of the biopharmaceutical company’s stock worth $1,055,000 after purchasing an additional 14,254 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Array BioPharma by 33.2% in the 2nd quarter. Goldman Sachs Group Inc. now owns 1,446,775 shares of the biopharmaceutical company’s stock worth $12,109,000 after purchasing an additional 360,535 shares during the last quarter. Finally, BlackRock Inc. boosted its position in shares of Array BioPharma by 1.0% in the 2nd quarter. BlackRock Inc. now owns 12,994,700 shares of the biopharmaceutical company’s stock worth $108,765,000 after purchasing an additional 125,563 shares during the last quarter. Institutional investors and hedge funds own 98.13% of the company’s stock.

Several research firms have recently issued reports on ARRY. Cantor Fitzgerald set a $15.00 price target on Array BioPharma and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. Zacks Investment Research lowered Array BioPharma from a “hold” rating to a “sell” rating in a research report on Thursday, January 4th. BidaskClub lowered Array BioPharma from a “hold” rating to a “sell” rating in a research report on Saturday, December 2nd. SunTrust Banks restated a “buy” rating and issued a $16.00 price target on shares of Array BioPharma in a research report on Wednesday, November 1st. Finally, Jefferies Group raised their price target on Array BioPharma to $13.00 and gave the stock a “buy” rating in a research report on Friday, December 22nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $14.10.

In related news, COO Andrew R. Robbins sold 282,874 shares of the firm’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of $10.72, for a total transaction of $3,032,409.28. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Ron Squarer sold 819,671 shares of the firm’s stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $10.86, for a total value of $8,901,627.06. The disclosure for this sale can be found here. Company insiders own 3.18% of the company’s stock.

Shares of Array BioPharma Inc. (ARRY) opened at $13.95 on Friday. The company has a market capitalization of $2,750.00, a price-to-earnings ratio of -18.85 and a beta of 1.91. Array BioPharma Inc. has a 12 month low of $6.73 and a 12 month high of $14.40. The company has a debt-to-equity ratio of 0.54, a quick ratio of 5.43 and a current ratio of 5.43.

Array BioPharma (NASDAQ:ARRY) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported ($0.22) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.22). The business had revenue of $29.75 million for the quarter, compared to the consensus estimate of $33.74 million. Array BioPharma had a negative return on equity of 158.70% and a negative net margin of 89.30%. The firm’s revenue was down 24.2% compared to the same quarter last year. During the same quarter last year, the business posted ($0.20) EPS. analysts expect that Array BioPharma Inc. will post -0.99 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “North Star Investment Management Corp. Buys 13,000 Shares of Array BioPharma Inc. (ARRY)” was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.com-unik.info/2018/01/12/north-star-investment-management-corp-buys-13000-shares-of-array-biopharma-inc-arry.html.

Array BioPharma Profile

Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).

Want to see what other hedge funds are holding ARRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Array BioPharma Inc. (NASDAQ:ARRY).

Institutional Ownership by Quarter for Array BioPharma (NASDAQ:ARRY)

What are top analysts saying about Array BioPharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Array BioPharma and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit